The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05563220
Recruitment Status : Recruiting
First Posted : October 3, 2022
Last Update Posted : May 20, 2024
Sponsor:
Information provided by (Responsible Party):
Stemline Therapeutics, Inc.

Tracking Information
First Submitted Date  ICMJE September 22, 2022
First Posted Date  ICMJE October 3, 2022
Last Update Posted Date May 20, 2024
Actual Study Start Date  ICMJE January 24, 2023
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 30, 2024)
  • Number of DLTs observed during the first cycle [ Time Frame: 28 days ]
    Number of dose-limiting toxicities during the first cycle
  • Estimation of PFS rate at 6 months [ Time Frame: 6 months ]
    PFS rate for each of the combination arms in patients who received prior ET and CDK4/6i in the metastatic setting
Original Primary Outcome Measures  ICMJE
 (submitted: September 28, 2022)
Determine the recommended Phase 2 dose (RP2D) of elacestrant in combination with each of the other study drugs [ Time Frame: 18 months ]
The recommended Phase 2 dose (RP2D) will be determined as the dose that is associated with less than 33% of patients (</+ 1 patient out of 6) experiencing a dose-limiting toxicities (DLTs) during the first cycle.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 30, 2024)
  • Standard PK parameters including AUC0-tau, Cmax, Tmax, and Ctrough [ Time Frame: 36 months ]
    The plasma PK of elacestrant and each of the combination drugs
  • Overall Response Rate [ Time Frame: 36 months ]
    Proportion of patients who achieve a best overall response (BOR) of confirmed partial response (PR) or complete response (CR)
  • Duration of Response [ Time Frame: 36 months ]
    Time from the date of the first documented CR/PR until the first radiological documentation of disease progression or death
  • Clinical Benefit Rate [ Time Frame: 36 months ]
    Proportion of patients who have the best overall response with a complete response, partial response or stable disease
  • Progression-free survival [ Time Frame: 36 months ]
    Time from the date of the first dose to the date of the first radiological documentation of disease progression or death, whichever occurs first
  • Overall Survival [ Time Frame: 36 months ]
    Time from the date of the first dose to the date of death from any cause
Original Secondary Outcome Measures  ICMJE
 (submitted: September 28, 2022)
  • Characterize the safety of elacestrant in combination with each of the other study drugs [ Time Frame: 24 months ]
    Number of Participants with Adverse events (AEs), serious adverse events (SAEs), with abnormal laboratory tests values, abnormal vital sign and abnormal electrocardiograms (ECG)
  • Pharmacokinetic assessment profile of elacestrant and each of the combination drugs. [ Time Frame: 36 months ]
    Describe the plasma pharmacokinetics (PK) of elacestrant and each of the combination drugs.
  • Overall Response Rate [ Time Frame: 36 months ]
    proportion of patients who achieve a best overall response (BOR) of confirmed partial response (PR) or complete response (CR)
  • Duration of Response [ Time Frame: 36 months ]
    time from the date of the first documented CR/PR until the first radiological documentation of disease progression or death
  • Clinical Benefit Rate [ Time Frame: 36 months ]
    Defined as the proportion of patients who have the best overall response with a complete response, partial response or stable disease.
  • Progression-free survival [ Time Frame: 36 months ]
    Time from the date of the first dose to the date of the first radiological documentation of disease progression or death, whichever occurs first
  • Overall Survival [ Time Frame: 36 months ]
    Time from the date of the first dose to the date of death from any cause
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Official Title  ICMJE A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Brief Summary This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Detailed Description

This is a multicenter, Phase 1b/2 trial. The Phase 1b aims at selecting the RP2D dose, defined as a dose that is associated with less than 33% of patients experiencing a DLT of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib, that is, ≤1 patient experiencing a DLT out of 6 DLT evaluable patients. For each combination, this phase will have between 1 and 3 cohorts of 6 DLT-evaluable patients each. The total number of DLT-evaluable patients in all the combinations will vary between 24 and 72.

The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

The treatment arms will be:

  • Arm A: 50 patients: elacestrant with alpelisib;
  • Arm B: 50 patients: elacestrant with everolimus;
  • Arm C: 60 patients (30 patients in each combination): elacestrant with either abemaciclib or ribociclib;
  • Arm D: 90 patients (30 patients in each combination): elacestrant with either palbociclib, abemaciclib, or ribociclib
  • Arm E: 60 patients: elacestrant with capivasertib

Phase 1b will have a total of 90 patients, while Phase 2 will have 310 patients for all treatment arm combinations.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Breast Cancer
  • Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: Elacestrant
    Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
  • Drug: Alpelisib
    Alpelisib 250 mg or 300 mg once daily in cycles of 28 days
    Other Name: Piqray
  • Drug: Everolimus
    Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
    Other Name: Afinitor
  • Drug: Ribociclib
    Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
    Other Name: Kisqali
  • Drug: Palbociclib
    Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
    Other Name: Ibrance
  • Drug: Capivasertib
    Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
    Other Name: Truqap
  • Drug: Abemaciclib
    Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
    Other Name: Verzenio
Study Arms  ICMJE
  • Experimental: Phase 1b Arm A: elacestrant with alpelisib
    Elacestrant Dihydrochloride 300 mg or 400 mg + Alpelisib 250 mg or 300 mg
    Interventions:
    • Drug: Elacestrant
    • Drug: Alpelisib
  • Experimental: Phase 1b Arm B: elacestrant with everolimus
    Elacestrant Dihydrochloride 300 mg or 400 mg + Everolimus 5.0 mg, 7.5 mg or possibly 10 mg
    Interventions:
    • Drug: Elacestrant
    • Drug: Everolimus
  • Experimental: Phase 1b Arm C: elacestrant with abemaciclib or ribociclib:

    Elacestrant Dihydrochloride 100 mg, 200 mg, 300 mg + Ribociclib 400 mg or possibly 600 mg

    The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)

    Interventions:
    • Drug: Elacestrant
    • Drug: Ribociclib
    • Drug: Abemaciclib
  • Experimental: Phase 1b Arm D: elacestrant with either palbociclib, abemaciclib, or ribociclib (no prior CDK4/6i)

    Elacestrant Dihydrochloride 300 mg or 400 mg + Palbociclib 100 mg,125 mg OR The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)

    Elacestrant 86 mg, 172 mg, 258 mg + Ribociclib 400 mg or possibly 600 mg

    Interventions:
    • Drug: Elacestrant
    • Drug: Ribociclib
    • Drug: Palbociclib
    • Drug: Abemaciclib
  • Experimental: Phase 1b Arm E:
    Elacestrant Dihydrochloride 300 mg, 400 mg + Capivasertib 200 mg, 320 mg, 400 mg
    Interventions:
    • Drug: Elacestrant
    • Drug: Capivasertib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 30, 2024)
400
Original Estimated Enrollment  ICMJE
 (submitted: September 28, 2022)
322
Estimated Study Completion Date  ICMJE August 31, 2026
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patient has signed the informed consent before all study specific activities are conducted.
  2. Women or men aged ≥18 years (or the minimum age of consent in accordance with the local law), at the time of informed consent signature. Female patients may be of any menopausal status.

    • Postmenopausal status is defined by:

      1. Age ≥60 years
      2. Age <60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) or a follicle-stimulating hormone (FSH) value >40 mIU/mL and an estradiol value<40 pg/mL (140 pmol/L) or in postmenopausal ranges per local reference ranges
      3. Documentation of prior surgical sterilization (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, at least 1 month before first dose of trial therapy).
    • Premenopausal and perimenopausal women (who do not fit postmenopausal criteria) and men must be concurrently receiving a luteinizing hormone-releasing hormone (LHRH) agonist initiated at least 4 weeks before the start of trial therapy and are planning to continue LHRH agonist treatment during the study treatment.
    • For perimenopausal women to be considered of non-childbearing potential, FSH levels must be >40 mIU/ml.
  3. Histopathological or cytological confirmed ER+, HER2-, breast cancer, per local laboratory, as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists(CAP) guidelines (Allison et al, 2020, Wolff et al, 2018). Note: In the context of this trial, ER status will be considered positive if ≥10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry, with or without PGR positivity. .
  4. At least 1 not previously irradiated measurable lesion as per RECIST version 1.1 and/or at least 1 lytic or mixed (lytic +sclerotic) bone lesion with identifiable soft tissue components meeting the definition of measurability by RECIST version 1.1 that can be evaluated by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.
  5. ECOG performance status of 0 or 1.
  6. Patient has adequate bone marrow and organ function, as defined by the following laboratory values:

    1. Absolute neutrophil count (ANC) ≥1.5 × 10^9/L
    2. Platelets ≥100 × 10^9/L
    3. Hemoglobin ≥9.0 g/dL
    4. Potassium, sodium, calcium (corrected for serum albumin) and magnesium CTCAE grade ≤1
    5. Creatinine is ≤ 1.5 x ULN or if creatinine is > 1.5 x ULN, then creatinine clearance must be ≥50 mL/min based on the Cockcroft-Gault formula. Note: C-G formula:

      • Creatinine clearance (male) = ([140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72)
      • Creatinine clearance (female) = (0.85 × [140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72)
    6. Serum albumin ≥3.0 g/dL (≥30 g/L)
    7. In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN. If the patient has liver metastases, ALT and AST ≤ 5 × ULN
    8. Total serum bilirubin <1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.

Exclusion Criteria:

  1. Active or newly diagnosed CNS metastases, including meningeal carcinomatosis. Note: Patients with stable brain or subdural metastases are allowed if the patient has completed local therapy and was on a stable or decreasing dose of corticosteroids at baseline for management of brain metastasis for at least 4 weeks before starting treatment in this study. The dose must be ≤2.0 mg/day of dexamethasone or equivalent. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
  2. Patients with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement >50%.
  3. Prior chemotherapy or elacestrant in the advanced/metastatic setting.
  4. Patients with known germline BRCA mutation without prior treatment with a PARP inhibitor before study entry.
  5. Prior therapy with elacestrant or other investigational selective estrogen receptor degraders (SERDs), or investigational alike agents such as selective estrogen receptor modulators (SERM), selective estrogen receptor covalent antagonists (SERCANs), complete estrogen receptor antagonists (CERANs), and proteolysis-targeting chimeras (PROTACs), in the metastatic setting. Prior treatment with fulvestrant is not exclusionary as it is an approved medication.
  6. Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy. Other malignancies with low risk of recurrence may be considered eligible with Sponsor approval.
  7. Uncontrolled significant active infections. • Patients with HBV and/or HCV infection must have undetectable viral load during screening.

    • Patients known to be HIV+ are allowed if they have undetectable viral load at baseline.

  8. Documented pneumonitis/ILD prior to Cycle 1 Day 1.
  9. Major surgery within 28 days before starting trial therapy.
  10. Inability to take oral medications, refractory or chronic nausea, gastrointestinal conditions (including significant gastric or bowel resection), history of malabsorption syndrome, or any other uncontrolled gastrointestinal condition that impact the absorption of the study drug.
  11. Known intolerance to elacestrant or any of its excipients.
  12. Pregnant and breast-feeding women are excluded from the study. In addition, women of childbearing potential are excluded who:

    • Within 28 days before starting trial therapy, did not use a highly effective method of contraception.

    • Do not agree to use a highly effective method of contraception (Appendix F) or abstain from heterosexual intercourse throughout the entire study period and for 120 days after trial therapy discontinuation.

  13. Men or women who do not agree to abstain from donating sperm or ova, or to use a highly effective method of contraception, during the course of the treatment period and for 120 days after the last dose of study treatment.
  14. Patient is currently receiving or received any of the following medications prior to first dose of trial therapy:

    • Anti-cancer therapy within 14 days (28 days for anticancer antibody based treatment) or 5 half-lives, whichever is shorter.

    Please note: Toxicity from prior therapy must be resolved to NCI CTCAE version 5.0 Grade ≤1, except alopecia and peripheral sensory neuropathy (Grade ≤2).

    • Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 14 days or 5 half-lives, whichever is shorter, (refer to http://medicine.iupui.edu/clinpharm/ddis/ or https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers).

    • Herbal preparations/medications within 7 days. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.

    • Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.

  15. Evidence of ongoing alcohol or drug abuse as assessed by the investigator.
  16. Any severe medical or psychiatric condition that, in the Investigator's opinion, would preclude the patient's participation in a clinical study.

Additional Eligibility for the Alpelisib Combination (Phase 1b and Arm A)

Inclusion:

In general, the SmPC of the respective combination drug should be consulted for instructions/restrictions with respect to interactions with concomitant medications.

  1. PIK3CA mutation by local laboratory assessment.
  2. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

  1. Prior therapy with alpelisib or any other PI3K inhibitor.
  2. Type 1 diabetes or uncontrolled type 2 diabetes (fasting plasma glucose level of >140 mg/dL [7.7 mmol/L], or glycosylated hemoglobin [HbA1c] level of >6.4%).
  3. Known intolerance to alpelisib or any of its excipients.
  4. Patient is currently receiving or received drugs known to be a BCRP inhibitor within 14 days or 5 half-lives, whichever is shorter, prior to first dose of trial therapy
  5. Patient has ongoing osteonecrosis of the jaw from previous or concurrent treatment with bisphosphonates or denosumab

Additional Eligibility for the Everolimus Combination (Phase 1b and Arm B)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

  1. Prior therapy with everolimus.
  2. Known intolerance to everolimus or any of its excipients.

Additional Eligibility for the Abemaciclib Combination (Arm C)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

  1. Prior therapy with abemaciclib in the advanced or metastatic setting. Adjuvant therapy with abemaciclib is exclusionary if the patient relapsed within the past 12 months.
  2. Known intolerance to abemaciclib or any of its excipients.

Additional Eligibility for the Ribociclib Combination (Phase 1b and Arm C)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

  1. Prior therapy with ribociclib in the metastatic setting. Prior adjuvant therapy with ribociclib is also exclusionary if the patient relapsed within the past 12 months.
  2. Known intolerance to ribociclib or any of its excipients.
  3. QTcF values ≥450 msec.
  4. Patients who already have or who are at significant risk of developing QTc prolongation, including patients with:

    • Long QT syndrome
    • Uncontrolled or significant cardiac disease including recent (6 months) myocardial infarction, congestive heart failure, unstable angina, and brady-arrhythmias
    • Electrolyte abnormalities
  5. Patient is currently receiving or received drugs known to prolong QT interval within 14 days or 5 half-lives, whichever is shorter, before the first dose of trial therapy.

Additional Eligibility for the Palbociclib Combination (Phase 1b)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting, one of which was in combination with a CDK4/6 inhibitor.

Exclusion:

  1. Prior therapy with palbociclib in the metastatic setting.
  2. Known intolerance to palbociclib or any of its excipients

Additional Eligibility for the Palbociclib Combination (Arm D)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting.

Exclusion:

  1. Prior therapy with a CDK4/6i in the metastatic setting.
  2. Known intolerance to palbociclib or any of its excipients.

Additional Eligibility for the Abemaciclib Combination (Arm D)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting.

Exclusion:

  1. Prior therapy with any CDK4/6i in the metastatic setting.
  2. Known intolerance to abemaciclib or any of its excipients.

Additional Eligibility for Ribociclib Combination (Arm D)

Inclusion:

1. One or up to two prior hormonal therapies in the advanced or metastatic setting.

Exclusion:

  1. Prior therapy with a CDK4/6i in the advanced or metastatic setting.
  2. Known intolerance to ribociclib or any of its excipients.
  3. QTcF values ≥450 msec.
  4. Patients who already have or who are at significant risk of developing QTc prolongation, including patients with:

    • Long QT syndrome
    • Uncontrolled or significant cardiac disease including recent (6 months) myocardial infarction, congestive heart failure, unstable angina, and brady-arrhythmias
    • Electrolyte abnormalities
  5. Patient is currently receiving or received drugs known to prolong QT interval within 14 days or 5 half-lives, whichever is shorter, before the first dose of trial therapy.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Stemline Trials 718-509-3742 trials@stemline.com
Contact: Mary Ann Samparani 646-731-2146 msamparani@stemline.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05563220
Other Study ID Numbers  ICMJE STML-ELA-0222
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Stemline Therapeutics, Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Stemline Therapeutics, Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Stemline Therapeutics, Inc.
Verification Date May 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP